Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the NHS 10 Year Plan includes a budget for the (a) use and (b) procurement of GLP-1 receptor agonists.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended in a NICE appraisal, including GLP-1 receptor agonists, usually within three months of final guidance.

NICE has recommended the GLP-1 receptor agonists liraglutide, semaglutide, and tirzepatide as clinically and cost-effective treatment options on the NHS for obesity. Liraglutide, brand name Saxenda, and semaglutide, brand name Wegovy, can currently only be accessed on the NHS via specialist weight management services, which are primarily based in hospital settings. In June 2025, the NHS began making tirzepatide, brand name Mounjaro, available through primary care. Approximately 220,000 adults will be considered for Mounjaro in the first three years, with access prioritised by clinical need.

The 10‑Year Health Plan is backed by an extra £29 billion in investment to fund the reforms, service improvements, and new technology required to deliver an NHS fit for the future. Through its implementation we are committed to further exploring how we can build on the current plans for the roll out of medicine like GLP-1 receptor agonists by working with industry to trial innovative approaches to treating obesity, as part of a rounded package of care. Additionally, we will explore a range of innovative commercial models that aim to increase patient access, whilst ensuring improved health outcomes and value for money.